|
private:euretos
|
3334296
|
Jun 12th, 2022 12:00AM
|
Euretos
|
1.8K
|
20.00
|
Open
|
Biotechnology
|
Jun 12th, 2022 12:51AM
|
Jun 12th, 2022 12:51AM
|
Data-Driven Disease Insight
We collaborate with our customers to unravel the complexities of human disease biology, reducing the risk and cost of therapy development. We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.
Euretos AI Platform
The Euretos AI Platform empowers researchers to draw evidence-based conclusions. It is used indepently but also as an integral part of our consulting projects. Leverage information from millions of machine-read publications and hundreds of data sources such as genetic, genomic and proteomic annotations, expression profiles, patents and much more. Generate hypotheses and evaluate evidence using a suite of applications including Search, Analytics, Knowledge Graph and many task-optimised Workflows.
Target Discovery / Indication Selection Consulting
In our projects we focus on target discovery and indication selection. In these areas, our computational disease models and translational biology consulting have been tried and tested in many collaborations with leading pharma and biotech companies. Our translational consultants will help you interpret the outcomes of our computational disease modeling. In addition, direct access to the Euretos AI Platform enables you to review results within the context of existing evidence from public biomolecular databases, publications and patents. Combine your proprietary data and therapeutic expertise with our disease models, translational consultants and AI platform to gain collaborative, data driven disease insights.
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
May 26th, 2022 12:00AM
|
Euretos
|
1.8K
|
20.00
|
Open
|
Biotechnology
|
May 25th, 2022 11:18PM
|
May 26th, 2022 10:02AM
|
Data-Driven Disease Insight
We collaborate with our customers to unravel the complexities of human disease biology, reducing the risk and cost of therapy development. We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.
Euretos AI Platform
The Euretos AI Platform empowers researchers to draw evidence-based conclusions. It is used indepently but also as an integral part of our consulting projects. Leverage information from millions of machine-read publications and hundreds of data sources such as genetic, genomic and proteomic annotations, expression profiles, patents and much more. Generate hypotheses and evaluate evidence using a suite of applications including Search, Analytics, Knowledge Graph and many task-optimised Workflows.
Target Discovery / Indication Selection Consulting
In our projects we focus on target discovery and indication selection. In these areas, our computational disease models and translational biology consulting have been tried and tested in many collaborations with leading pharma and biotech companies. Our translational consultants will help you interpret the outcomes of our computational disease modeling. In addition, direct access to the Euretos AI Platform enables you to review results within the context of existing evidence from public biomolecular databases, publications and patents. Combine your proprietary data and therapeutic expertise with our disease models, translational consultants and AI platform to gain collaborative, data driven disease insights.
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Mar 28th, 2022 12:00AM
|
Euretos
|
1.7K
|
19.00
|
Open
|
Biotechnology
|
Mar 28th, 2022 07:40PM
|
Mar 28th, 2022 07:40PM
|
Data-Driven Disease Insight
We collaborate with our customers to unravel the complexities of human disease biology, reducing the risk and cost of therapy development. We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.
Euretos AI Platform
The Euretos AI Platform empowers researchers to draw evidence-based conclusions. It is used indepently but also as an integral part of our consulting projects. Leverage information from millions of machine-read publications and hundreds of data sources such as genetic, genomic and proteomic annotations, expression profiles, patents and much more. Generate hypotheses and evaluate evidence using a suite of applications including Search, Analytics, Knowledge Graph and many task-optimised Workflows.
Target Discovery / Indication Selection Consulting
In our projects we focus on target discovery and indication selection. In these areas, our computational disease models and translational biology consulting have been tried and tested in many collaborations with leading pharma and biotech companies. Our translational consultants will help you interpret the outcomes of our computational disease modeling. In addition, direct access to the Euretos AI Platform enables you to review results within the context of existing evidence from public biomolecular databases, publications and patents. Combine your proprietary data and therapeutic expertise with our disease models, translational consultants and AI platform to gain collaborative, data driven disease insights.
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Mar 10th, 2022 12:00AM
|
Euretos
|
1.7K
|
19.00
|
Open
|
Biotechnology
|
Mar 10th, 2022 06:48PM
|
Mar 10th, 2022 06:48PM
|
Data-Driven Disease Insight
We collaborate with our customers to unravel the complexities of human disease biology, reducing the risk and cost of therapy development. We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.
Euretos AI Platform
The Euretos AI Platform empowers researchers to draw evidence-based conclusions. It is used indepently but also as an integral part of our consulting projects. Leverage information from millions of machine-read publications and hundreds of data sources such as genetic, genomic and proteomic annotations, expression profiles, patents and much more. Generate hypotheses and evaluate evidence using a suite of applications including Search, Analytics, Knowledge Graph and many task-optimised Workflows.
Target Discovery / Indication Selection Consulting
In our projects we focus on target discovery and indication selection. In these areas, our computational disease models and translational biology consulting have been tried and tested in many collaborations with leading pharma and biotech companies. Our translational consultants will help you interpret the outcomes of our computational disease modeling. In addition, direct access to the Euretos AI Platform enables you to review results within the context of existing evidence from public biomolecular databases, publications and patents. Combine your proprietary data and therapeutic expertise with our disease models, translational consultants and AI platform to gain collaborative, data driven disease insights.
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Feb 14th, 2022 12:00AM
|
Euretos
|
1.7K
|
19.00
|
Open
|
Biotechnology
|
Feb 14th, 2022 11:56AM
|
Feb 14th, 2022 11:56AM
|
Data-Driven Disease Insight
We collaborate with our customers to unravel the complexities of human disease biology, reducing the risk and cost of therapy development. We generate data driven disease insights through a unique combination of AI driven, computational disease models, translational biology consultancy and direct access to the Euretos AI platform. This empowers our customers to draw their own conclusions and take a data driven approach to disease and drug research.
Euretos AI Platform
The Euretos AI Platform empowers researchers to draw evidence-based conclusions. It is used indepently but also as an integral part of our consulting projects. Leverage information from millions of machine-read publications and hundreds of data sources such as genetic, genomic and proteomic annotations, expression profiles, patents and much more. Generate hypotheses and evaluate evidence using a suite of applications including Search, Analytics, Knowledge Graph and many task-optimised Workflows.
Target Discovery / Indication Selection Consulting
In our projects we focus on target discovery and indication selection. In these areas, our computational disease models and translational biology consulting have been tried and tested in many collaborations with leading pharma and biotech companies. Our translational consultants will help you interpret the outcomes of our computational disease modeling. In addition, direct access to the Euretos AI Platform enables you to review results within the context of existing evidence from public biomolecular databases, publications and patents. Combine your proprietary data and therapeutic expertise with our disease models, translational consultants and AI platform to gain collaborative, data driven disease insights.
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Oct 17th, 2021 12:00AM
|
Euretos
|
1.5K
|
20.00
|
Open
|
Biotechnology
|
Oct 16th, 2021 09:27PM
|
Oct 16th, 2021 09:27PM
|
Euretos provides AI driven contract research services and cloud access to the Euretos AI Platform to enable preclinical discovery & clinical validation of targets, biomarkers and indications. Our applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.
Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence.
State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.
These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.
Euretos has taken a unique approach as we are the only AI vendor in the drug development area:
- That is a pure products & service provider without developing their own pipeline
- That uses Machine Reading for data integration which provides a very significant increase in data quality
- To have developed an end-user cloud application for biological researchers (i.e. non-data scientists) therefore impacting all levels of the R&D organisation
- With a singular focus on systems biology and molecular level insight into diseases and the biological effects of drug therapies
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Sep 10th, 2021 12:00AM
|
Euretos
|
1.5K
|
19.00
|
Open
|
Biotechnology
|
Sep 9th, 2021 09:56PM
|
Sep 9th, 2021 09:56PM
|
Euretos provides AI driven contract research services and cloud access to the Euretos AI Platform to enable preclinical discovery & clinical validation of targets, biomarkers and indications. Our applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.
Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence.
State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.
These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.
Euretos has taken a unique approach as we are the only AI vendor in the drug development area:
- That is a pure products & service provider without developing their own pipeline
- That uses Machine Reading for data integration which provides a very significant increase in data quality
- To have developed an end-user cloud application for biological researchers (i.e. non-data scientists) therefore impacting all levels of the R&D organisation
- With a singular focus on systems biology and molecular level insight into diseases and the biological effects of drug therapies
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Aug 26th, 2021 12:00AM
|
Euretos
|
1.4K
|
19.00
|
Open
|
Biotechnology
|
Aug 26th, 2021 05:25PM
|
Aug 26th, 2021 05:25PM
|
Euretos provides AI driven contract research services and cloud access to the Euretos AI Platform to enable preclinical discovery & clinical validation of targets, biomarkers and indications. Our applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.
Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence.
State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.
These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.
Euretos has taken a unique approach as we are the only AI vendor in the drug development area:
- That is a pure products & service provider without developing their own pipeline
- That uses Machine Reading for data integration which provides a very significant increase in data quality
- To have developed an end-user cloud application for biological researchers (i.e. non-data scientists) therefore impacting all levels of the R&D organisation
- With a singular focus on systems biology and molecular level insight into diseases and the biological effects of drug therapies
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Aug 25th, 2021 12:00AM
|
Euretos
|
1.4K
|
19.00
|
Open
|
Biotechnology
|
Aug 24th, 2021 08:45PM
|
Aug 24th, 2021 08:45PM
|
Euretos provides AI driven contract research services and cloud access to the Euretos AI Platform to enable preclinical discovery & clinical validation of targets, biomarkers and indications. Our applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.
Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence.
State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.
These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.
Euretos has taken a unique approach as we are the only AI vendor in the drug development area:
- That is a pure products & service provider without developing their own pipeline
- That uses Machine Reading for data integration which provides a very significant increase in data quality
- To have developed an end-user cloud application for biological researchers (i.e. non-data scientists) therefore impacting all levels of the R&D organisation
- With a singular focus on systems biology and molecular level insight into diseases and the biological effects of drug therapies
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|
|
private:euretos
|
3334296
|
Aug 17th, 2021 12:00AM
|
Euretos
|
1.3K
|
20.00
|
Open
|
Biotechnology
|
Aug 17th, 2021 07:44PM
|
Aug 17th, 2021 07:44PM
|
Euretos provides AI driven contract research services and cloud access to the Euretos AI Platform to enable preclinical discovery & clinical validation of targets, biomarkers and indications. Our applications and services give researchers fundamental and novel insights into the systems biological, molecular mechanisms that drive phenotypes, disease pathologies, toxicities and drug response.
Euretos uses Machine Reading to semantically integrate over 275 public life sciences data and textual sources to provide the largest knowledge base where multi omics data is interlinked to literature, patents, experimental and clinical evidence.
State-of-the-art Machine & Deep Learning algorithms for cell type deconvolution, co-expression prediction and target perturbation analysis leverage this unique knowledge base to create highly insightful molecular disease models.
These unique assets enable (pre)clinical researchers to take a translational systems biology approach by connecting multi-omics interactions, through cell-type involvement, to downstream pathways, phenotypes and disease pathologies.
Euretos has taken a unique approach as we are the only AI vendor in the drug development area:
- That is a pure products & service provider without developing their own pipeline
- That uses Machine Reading for data integration which provides a very significant increase in data quality
- To have developed an end-user cloud application for biological researchers (i.e. non-data scientists) therefore impacting all levels of the R&D organisation
- With a singular focus on systems biology and molecular level insight into diseases and the biological effects of drug therapies
|
Open
|
Target Identification, Biomarker Discovery, Drug Repositioning, Multi Omics Analysis, Life Sciences Data Integration, Computational Biology, Big Data Analytics, Literature Search, Semantic Integration
|
Open
|
Yalelaan 1
|
Utrecht
|
|
NL
|
3584
|
|
Euretos
|
|
|